Our co-hosts discuss the currently active & accruing NRG-GU012 study, also known as the "SAMURAI" study. This study is assessing if stereotactic ablative radiotherapy to the primary tumor in combination with immunotherapy improves outcomes when compared to immunotherapy by itself for patients who have metastatic, unresected, renal cell carcinoma.